The Organ That Sets the Ceiling

Of all the organs, the brain is the one that decides whether a long life is worth living. You can replace a failing heart valve or a failing kidney, but a body kept alive without a functioning mind is not the kind of longevity anyone hopes for. This is why neurology sits at the center of any serious conversation about living longer. It is also why it is the hardest problem in this whole project. The brain is protected, intricate, and slow to heal, and for most of medical history we could treat its diseases only by managing symptoms.

Neurodegeneration, and why it is so stubborn

Neurodegenerative diseases, of which Alzheimer's is the most common, involve the gradual loss of neurons and the connections between them. In Alzheimer's, two proteins build up where they should not. One, called amyloid, clumps into deposits known as plaques between brain cells. The other, called tau, forms tangles inside them. For a long time medicine could do nothing about this underlying biology. The available drugs eased symptoms for a while but did not touch the disease itself.

For the first time, a handful of treatments aim at the disease rather than its shadow.

The first disease-modifying drugs

That has begun to change. Two anti-amyloid antibodies, lecanemab (approved in 2023) and donanemab (approved in 2024), are the first treatments shown to slow early Alzheimer's. Approved12 Antibodies are the immune system's targeting proteins, and these are laboratory-made versions that latch onto amyloid and mark it for removal. It is important to be precise about what they do and do not do. They slow decline by roughly a quarter to a third over eighteen months. They do not reverse damage already done, and they do not stop the disease. They buy time and preserve function for longer, which is meaningful, but modest.

They also carry real risks, most notably a side effect called ARIA, which means swelling or small bleeds in the brain that show up on scans. It is more common in people carrying a gene variant called APOE4, the strongest common genetic risk factor for Alzheimer's. These drugs are only for people in the earliest stages, and they require careful patient selection and regular monitoring. The honest summary is that this is a real beginning, not an arrival.

Catching it earlier

One quieter advance may matter as much as the drugs. A simple blood test can now pick up the same proteins with an accuracy approaching that of expensive brain scans. Because these treatments only help in the earliest stages, being able to identify the disease sooner, and more cheaply, is part of what makes them usable at all.

Rescue, not just slower decline

Not all brain injury is slow. Stroke is the sudden version, a blood vessel in the brain blocked or burst, and here the story of the last two decades is one of real success. Clot-dissolving drugs and, more dramatically, mechanical thrombectomy, a procedure in which surgeons thread a device up into the brain and physically pull the clot out, have turned Approved3 some strokes that once caused severe disability into events people recover from, provided treatment comes fast enough. Time is the currency. The faster blood flow is restored, the more brain is saved.